These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38128187)

  • 1. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review.
    Wang Q; Liu J; Chen Z; Zheng J; Wang Y; Dong J
    Biomed Pharmacother; 2024 Jan; 170():116021. PubMed ID: 38128187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review).
    Gao W; Wang J; Xu Y; Yu H; Yi S; Bai C; Cong Q; Zhu Y
    Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38818815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Liao W; Du J; Wang Z; Feng Q; Liao M; Liu H; Yuan K; Zeng Y
    Int J Cancer; 2022 Aug; 151(3):337-347. PubMed ID: 35460073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
    Bao MH; Wong CC
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
    Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma.
    Wang Q; Tan Y; Jiang T; Wang X; Li Q; Li Y; Dong L; Liu X; Xu G
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma.
    Bergamini C; Leoni I; Rizzardi N; Melli M; Galvani G; Coada CA; Giovannini C; Monti E; Liparulo I; Valenti F; Ferracin M; Ravaioli M; Cescon M; Vasuri F; Piscaglia F; Negrini M; Stefanelli C; Fato R; Gramantieri L; Fornari F
    J Exp Clin Cancer Res; 2023 Jun; 42(1):145. PubMed ID: 37301960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
    J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
    Tian Y; Lei Y; Fu Y; Sun H; Wang J; Xia F
    Curr Cancer Drug Targets; 2022; 22(6):454-462. PubMed ID: 35362393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
    Barot S; Abo-Ali EM; Zhou DL; Palaguachi C; Dukhande VV
    Exp Cell Res; 2019 Aug; 381(2):288-300. PubMed ID: 31128107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
    Xu K; Xia P; Chen X; Ma W; Yuan Y
    Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
    Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
    Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance.
    Fekir K; Dubois-Pot-Schneider H; Désert R; Daniel Y; Glaise D; Rauch C; Morel F; Fromenty B; Musso O; Cabillic F; Corlu A
    Cancer Res; 2019 Apr; 79(8):1869-1883. PubMed ID: 30837223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.
    Li A; Wang R; Zhao Y; Zhao P; Yang J
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.